Skip to main content
Fig. 5 | Acta Neuropathologica Communications

Fig. 5

From: LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

Fig. 5

LRRK2 inhibition does not alter pathology induced by human Lewy body α-synuclein. a A schematic representation of pathological α-synuclein purification from human cortical tissue. b Primary hippocampal neurons from CD1 pups were treated with 100 nM LRRK2 inhibitors or a vehicle control. Two days later, neurons were treated with 40 ng/mL human LB α-synuclein and allowed to age a further 14 days prior to fixation and staining for pS129 α-synuclein (magenta), MAP2 (gray) and NeuN (blue). No large differences can be observed in the type or abundance of α-synuclein pathology. c Quantification of α-synuclein pathology reveals an increase in neurons treated with LB α-synuclein compared to those treated with PBS (**p < 0.01), but no change in response to LRRK2 inhibition. MAP2 area (d) and neuron number (e) are also not altered meaningfully in response to LRRK2 inhibition. (N = 11–12 biological replicates treated with LB α-synuclein from 4 separate cases (2 AD, 1 PDD, 1 DLB). Means + s.e.m.; all values are normalized to neurons treated with LB α-synuclein and DMSO. Scale bars = 50 μm

Back to article page